Covid shots designed to protect against the omicron variant trigger a weaker immune response against the rapidly emerging BQ.1.1 subvariant than the previously dominant strain, according to a new lab study.
A study yesterday in JAMA Internal Medicine shows women and racial minorities were underrepresented in both COVID-19 clinical treatment trials and in disease prevention trials.
The research was conducted by a team from the Fred Hutchinson Cancer Center, as well researchers from Beijing and London.
Recent Comments